Press Releases

Press Releases

Samsung Biologics Ranks No.1 in Pharmaceutical Brand Reputation List in Korea

Songdo, S. Korea, 09 March 2020 – Samsung Biologics (207940.KS), a world-class CMO, CDO, and CRO, announced that it took first place in the domestic brand reputation list, ranking among all pharmaceutical companies listed on the Korea stock exchange.

 

The Brand Reputation Index (BRI) is put together every month by the Korea Corporate Reputation Research Institute, based on its consumer activity-related big data analyses in multiple categories including Participation index, Communication index, Community index, and Market index.

 

Samsung Biologics was ranked first place in February with a BRI of 8,311,153, followed by Celltrion Healthcare in second, and Chong Kun Dang Pharmaceutical in third.

 

Since the company’s initial listing in 2016, Samsung Biologics has shown steady growth in its performance – revenue and profits have been climbing, debt ratio improved, and the yearly number of contracts signed jumped 30% for CMO and 740% for CDO from 2018 to 2019. Samsung Biologics has also been actively monitoring and communicating operational countermeasures amidst the recent COVID-19 crisis, working to address both client and public concerns.


Songdo, S. Korea, 09 March 2020 – Samsung Biologics (207940.KS), a world-class CMO, CDO, and CRO, announced that it took first place in the domestic brand reputation list, ranking among all pharmaceutical companies listed on the Korea stock exchange.

 

The Brand Reputation Index (BRI) is put together every month by the Korea Corporate Reputation Research Institute, based on its consumer activity-related big data analyses in multiple categories including Participation index, Communication index, Community index, and Market index.

 

Samsung Biologics was ranked first place in February with a BRI of 8,311,153, followed by Celltrion Healthcare in second, and Chong Kun Dang Pharmaceutical in third.

 

Since the company’s initial listing in 2016, Samsung Biologics has shown steady growth in its performance – revenue and profits have been climbing, debt ratio improved, and the yearly number of contracts signed jumped 30% for CMO and 740% for CDO from 2018 to 2019. Samsung Biologics has also been actively monitoring and communicating operational countermeasures amidst the recent COVID-19 crisis, working to address both client and public concerns.


SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION